Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Kathleen Sebelius, a director at Humacyte, Inc. (NASDAQ:HUMA), recently acquired 50,000 shares of the company's common stock. The transaction, which took place on April 8, 2025, was executed at a price of $1.32 per share, resulting in a total purchase value of $66,000. The purchase comes as the stock trades near its 52-week low of $1.18, with analyst price targets ranging from $3 to $25. According to InvestingPro data, the stock has declined over 77% in the past six months. Following this acquisition, Sebelius now holds a total of 91,207 shares directly. This move reflects her continued investment in the biotechnology company based in Durham, North Carolina, which currently has a market capitalization of $179 million. Want deeper insights into insider trading patterns and 12 more exclusive InvestingPro Tips for HUMA? Access the comprehensive Pro Research Report available for this stock.
In other recent news, Humacyte reported a narrower fourth-quarter loss of $0.16 per share, outperforming analyst expectations of a $0.25 per share loss, although the company did not generate any revenue during the quarter. This comes after the FDA approved Symvess, Humacyte's bioengineered blood vessel product, in December, with its commercial launch beginning in late February. Despite the lack of revenue, CEO Laura Niklason expressed optimism, noting that 34 hospitals have initiated the approval process to purchase Symvess, with three hospitals having completed approvals. For the full year 2024, Humacyte reported a net loss of $148.7 million, up from a $110.8 million loss in 2023, largely due to increased research and development expenses.
Humacyte ended 2024 with $95.3 million in cash and equivalents and raised an additional $46.6 million through a public stock offering in March 2025. Benchmark analysts maintained a Buy rating on Humacyte, with a price target of $17.00, highlighting the company's strategic plans, including filing an IND application for coronary artery bypass grafting in 2025 and a supplemental BLA for dialysis AV access in late 2026. BTIG analyst Ryan Zimmerman also maintained a Buy rating but lowered the price target from $10.00 to $8.00, citing early commercial traction as evidence of the product's potential impact. Humacyte's ongoing efforts and product acceptance within the medical community are seen as positive indicators of the company's growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.